Flyte Aviation, Inc.
Close on Oct 19, 2026
- Market cap
- $2.26M
- P/E (TTM)
- –
- Dividend yield
- –
About Flyte Aviation
Surgical & Medical Instruments & Apparatus, SIC 3841
Catheter Precision, Inc. designs, manufactures, and markets medical technologies focused on cardiac electrophysiology, with an emphasis on the catheter ablation market. Its primary product is the VIVO System, a non-invasive imaging platform that utilizes three-dimensional cardiac mapping to localize the origin of ventricular arrhythmias prior to electrophysiology procedures. The company also produces LockeT, a sterile suture retention device engineered to aid wound healing, temporarily secure sutures, and promote hemostasis following catheterization. Additionally, the company operates a private aviation charter business called FLYTE. Catheter Precision primarily serves hospitals that operate cardiac electrophysiology laboratories.
The company markets its products domestically through direct sales personnel and internationally via third-party distributors. The VIVO system has been utilized across eleven countries, including clinical use and placements in the United States, the United Kingdom, and the European Union. Assembly, inventory management, and product fulfillment for VIVO take place in an approximate 2,000-square-foot facility situated in Fort Mill, South Carolina.
Summary of the business section of Flyte Aviation's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Flyte Aviation, Inc.
- Founded
- 2018
- Headquarters
- Fort Mill, SC
- Address
- 1670 Highway 160 West, Suite 205 29708
- Phone
- (973) 691-2000
- Employees
- 17, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, East Brunswick, New Jersey
Stock & identifiers
- Ticker
- VJET
- Other tickers
- VTAK
- Exchange
- NYSE
- IPO date
- Sep 27, 2018
- Shares outstanding
- 14M, Aug 10, 2026
- Public float
- $3.90M, Jun 30, 2024
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Oct 5, 2026; 1-for-10 reverse, Oct 5, 2026; 1-for-19 reverse, Nov 13, 2025; 1-for-19 reverse, Aug 15, 2025; 1-for-10 reverse, Jul 15, 2024; 1-for-50 reverse, Nov 14, 2022; 1-for-50 reverse, Oct 3, 2022; 1-for-25 reverse, Dec 31, 2020; 1-for-25 reverse, Nov 17, 2020
- SEC CIK
- 1716621
- EIN
- 38-3661826
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David A. Jenkins | Chairman of the Board and CEO, Director | 48,487 |
| Philip J. Anderson | Chief Financial Officer | 0 |
| Marie-Claude Jacques | Chief Commercial Officer | 0 |
| Andrew Arno | Director | 0 |
| Martin J. Colombatto | Director | 57 |
| James Joseph Caruso | Director | 50 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 | – | $0 | $287.92K | $-0 | – |
| FY2024 Mr Jenkins | $300.00K | $300.00K | $287.92K | $-0 | – |
| FY2024 Mr Mc Guire | $0 | $300.00K | $287.92K | $-0 | – |
| FY2023 Mr Jenkins | $300.00K | $300.00K | $189.66K | $1 | – |
| FY2023 Mr Mc Guire | $1.92M | $1.92M | $189.66K | $1 | – |
| FY2022 Mr Jenkins | $0 | $0 | $234.88K | $8 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 18, 2026, we had a total of 17 employees, including 17 full-time employees, which include finance and administrative, research and development, sales and marketing and clinical professionals.”
Corporate history
Events identified from SEC filings